A head-to-head randomized trial answers a different question from comparing two separate placebo-controlled studies. SURMOUNT-5 directly compared two treatment strategies. Primary report
Study snapshot
The open-label trial randomized 751 adults with obesity but without type 2 diabetes to maximum-tolerated study regimens of tirzepatide or semaglutide. At 72 weeks, mean weight reduction was greater with tirzepatide. The primary endpoint was percentage weight change; waist circumference and weight-reduction thresholds were additional outcomes. Primary report
Our appraisal: superiority is endpoint specific
The comparison provides direct evidence for the tested weight endpoint in this population. It does not establish that one treatment is superior for every clinical outcome, every patient, every formulation, or every available regimen.
The open-label design should also remain visible. Randomization addresses baseline allocation, while masking addresses different potential influences after assignment. An objective weight measurement does not make adherence, discontinuation, cointerventions, and reported adverse events irrelevant.
Maximum tolerated treatment is a strategy rather than one identical exposure for every participant. Interpretation should examine achieved regimens and the analysis of people who discontinued or could not reach the intended treatment level. These features are part of what the trial compared.
The practical evidence summary should retain absolute estimates and uncertainty rather than only a “winner” label. Full review must include adverse events, reasons for stopping, missing-data assumptions, and the distinction between average response and individual variability. This study is not an instruction to switch medicines or to substitute unverified products for the trial preparations.
Frequently asked questions
Was this a direct randomized comparison?
Yes.
Was treatment assignment masked?
No. The trial was open label.
Did participants have type 2 diabetes?
The study excluded that population.
Which group had greater mean weight reduction?
Tirzepatide in the reported 72-week comparison.
Does that establish superiority for all outcomes?
No.
Is maximum tolerated treatment identical for every participant?
No. It is a treatment strategy within protocol limits.
What belongs beside the efficacy result?
Uncertainty, discontinuation, tolerability, missing outcomes, and the exact regimens compared.